Scrip is part of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction
UsernamePublicRestriction

Janssen's Zytiga fails to impress NICE

This article was originally published in Scrip

Executive Summary

Janssen Cilag has failed to convince NICE, the health technology appraisal institute for England and Wales, that its oral prostate cancer drug Zytiga (abiraterone), provides enough benefit to justify the cost. Today's draft recommendations come despite the offer of a patient access scheme and NICE's acknowledgement that the drug does prolong life.

Advertisement

Topics

Related Companies

Advertisement
UsernamePublicRestriction

Register

SC016125

Ask The Analyst

Please Note: Click here for more information on the Ask the Analyst service.

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel